WO2001069261A3 - Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire - Google Patents

Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire Download PDF

Info

Publication number
WO2001069261A3
WO2001069261A3 PCT/GB2001/001106 GB0101106W WO0169261A3 WO 2001069261 A3 WO2001069261 A3 WO 2001069261A3 GB 0101106 W GB0101106 W GB 0101106W WO 0169261 A3 WO0169261 A3 WO 0169261A3
Authority
WO
WIPO (PCT)
Prior art keywords
vascular dementia
treatment
vpis
diagnosis
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/001106
Other languages
English (en)
Other versions
WO2001069261A2 (fr
Inventor
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0006285A external-priority patent/GB0006285D0/en
Priority claimed from GB0028734A external-priority patent/GB0028734D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Priority to AU2001240820A priority Critical patent/AU2001240820A1/en
Priority to EP01911898A priority patent/EP1264183A2/fr
Publication of WO2001069261A2 publication Critical patent/WO2001069261A2/fr
Publication of WO2001069261A3 publication Critical patent/WO2001069261A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention concerne des méthodes et des compositions convenant dans le criblage, le diagnostic et le pronostic de la démence vasculaire, ainsi que pour la surveillance de l'efficacité d'un traitement de la démence vasculaire, l'identification de patients susceptibles de réagir à un traitement thérapeutique particulier et le développement de médicaments. L'invention concerne également les caractéristiques associées à la démence vasculaire (VF), détectables par électrophorèse bidimensionnelle du liquide céphalo-rachidien, du sérum ou du plasma. L'invention concerne en outre des isoformes de protéines associées à la démence vasculaire (VPI), pouvant être détectées dans le liquide céphalo-rachidien, le sérum ou le plasma, ainsi que des préparations contenant des VPI isolées, des anticorps immunospécifiques pour ces VPI et des kits contenant les éléments susmentionnés.
PCT/GB2001/001106 2000-03-15 2001-03-14 Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire Ceased WO2001069261A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001240820A AU2001240820A1 (en) 2000-03-15 2001-03-14 Proteins, genes and their use for diagnosis and treatment of vascular dementia
EP01911898A EP1264183A2 (fr) 2000-03-15 2001-03-14 Le diagnostic et le traitement de la demence vasculaire

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0006285A GB0006285D0 (en) 2000-03-15 2000-03-15 Proteins and their use for diagnosis and treatment of vascular dementia
GB0006285.1 2000-03-15
GB0028734A GB0028734D0 (en) 2000-11-24 2000-11-24 Markers for vascular dementia
GB0028734.2 2000-11-24
US72439100A 2000-11-28 2000-11-28
US09/724,391 2000-11-28

Publications (2)

Publication Number Publication Date
WO2001069261A2 WO2001069261A2 (fr) 2001-09-20
WO2001069261A3 true WO2001069261A3 (fr) 2002-05-16

Family

ID=27255598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001106 Ceased WO2001069261A2 (fr) 2000-03-15 2001-03-14 Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire

Country Status (3)

Country Link
EP (1) EP1264183A2 (fr)
AU (1) AU2001240820A1 (fr)
WO (1) WO2001069261A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054080A2 (fr) * 2000-12-29 2002-07-11 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire
US20030100012A1 (en) * 2001-11-23 2003-05-29 George Jackowski Plasma protease C1 biopolymer markers predictive of alzheimers disease
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
WO2004001421A2 (fr) * 2002-06-21 2003-12-31 Innogenetics N.V. Procede de diagnostic et diagnostic differentiel des maladies neurologiques
US11543418B2 (en) 2017-07-13 2023-01-03 Kazuhiko Uchida Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker
CN111773204B (zh) * 2019-04-03 2023-01-24 上海市浦东新区浦南医院 二氯乙酸钠在制备治疗血管性痴呆药物中的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002045A2 (fr) * 1993-07-09 1995-01-19 Celltech Limited Antagonistes de gelatinase utilises dans le traitement de cancer
WO1995030433A1 (fr) * 1994-05-09 1995-11-16 Research Development Foundation Nouvelle proteine endotheliale du cerveau et procedes d'utilisation de cette proteine
WO1995035373A2 (fr) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Molecules d'acide nucleique codant la contactine humaine
WO1996037776A1 (fr) * 1995-05-26 1996-11-28 Sugen, Inc. Ligands fonctionnels de la contactine molecule de reconnaissance des cellules axonales
EP0796913A2 (fr) * 1996-03-19 1997-09-24 Otsuka Pharmaceutical Co., Ltd. Protéine stimulant la dissociation du GDP, protéine d'assemblage de nucléosome spécifique au cerveau, enzyme de conjugaison d'ubiquitine spécifique aux muscles du squelette, protéine de prolifération de cellule, phosphatidylinositolkinase, protéines apparentés à nel
WO1998027226A2 (fr) * 1996-12-16 1998-06-25 Nova Molecular, Inc. Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique
WO2000070099A2 (fr) * 1999-05-19 2000-11-23 Mitokor Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives
WO2001026671A1 (fr) * 1999-10-12 2001-04-19 Smithkline Beecham Corporation Procedes de traitement au moyen d'inhibiteurs doubles de metalloproteinase-2 matricielle et de metalloproteinase-9 matricielle

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002045A2 (fr) * 1993-07-09 1995-01-19 Celltech Limited Antagonistes de gelatinase utilises dans le traitement de cancer
WO1995030433A1 (fr) * 1994-05-09 1995-11-16 Research Development Foundation Nouvelle proteine endotheliale du cerveau et procedes d'utilisation de cette proteine
WO1995035373A2 (fr) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Molecules d'acide nucleique codant la contactine humaine
WO1996037776A1 (fr) * 1995-05-26 1996-11-28 Sugen, Inc. Ligands fonctionnels de la contactine molecule de reconnaissance des cellules axonales
EP0796913A2 (fr) * 1996-03-19 1997-09-24 Otsuka Pharmaceutical Co., Ltd. Protéine stimulant la dissociation du GDP, protéine d'assemblage de nucléosome spécifique au cerveau, enzyme de conjugaison d'ubiquitine spécifique aux muscles du squelette, protéine de prolifération de cellule, phosphatidylinositolkinase, protéines apparentés à nel
WO1998027226A2 (fr) * 1996-12-16 1998-06-25 Nova Molecular, Inc. Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique
WO2000070099A2 (fr) * 1999-05-19 2000-11-23 Mitokor Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives
WO2001026671A1 (fr) * 1999-10-12 2001-04-19 Smithkline Beecham Corporation Procedes de traitement au moyen d'inhibiteurs doubles de metalloproteinase-2 matricielle et de metalloproteinase-9 matricielle

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ABRAHAMSON M ET AL: "MOLECULAR CLONING AND SEQUENCE ANALYSIS OF CDNA CODING FOR THE PRECURSOR OF THE HUMAN CYSTEINE PROTEINASE INHIBITOR CYSTATIN C", FEBS LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 216, no. 2, 1 June 1987 (1987-06-01), pages 229 - 233, XP002038720, ISSN: 0014-5793 *
ARAI HIROYUKI ET AL: "No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.", NEUROSCIENCE LETTERS, vol. 256, no. 3, 13 November 1998 (1998-11-13), pages 174 - 176, XP001011876, ISSN: 0304-3940 *
BLENNOW K ET AL: "Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood-brain barrier.", NEURODEGENERATION, vol. 4, no. 2, 1995, pages 187 - 193, XP001011872, ISSN: 1055-8330 *
CHO HIROYUKI ET AL: "Biphasic changes in F3/contactin expression in the gerbil hippocampus after transient ischemia.", EXPERIMENTAL BRAIN RESEARCH, vol. 122, no. 2, 1998, pages 227 - 234, XP001024392, ISSN: 0014-4819 *
DATABASE SWISS-PROT XP002186525 *
DATABASE SWISS-PROT XP002186526 *
DATABASE SWISS-PROT XP002186527 *
DATABASE SWISS-PROT XP002186528 *
DATABASE SWISS-PROT XP002186529 *
GOHLKE ULRICH ET AL: "The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): Structural implications for its function.", FEBS LETTERS, vol. 378, no. 2, 1996, pages 126 - 130, XP002057541, ISSN: 0014-5793 *
KACZOREK M ET AL: "MOLECULAR CLONING AND SYNTHESIS OF BIOLOGICALLY ACTIVE HUMAN TISSUE INHIBITOR OF METALLOPROTEINASES IN YEAST", BIO-TECHNOLOGY (NEW YORK), vol. 5, no. 6, 1987, pages 595 - 598, XP001042262, ISSN: 0733-222X *
KURODA SHUN'ICHI ET AL: "Biochemical characterization and expression analysis of neural thrombospondin-1-like proteins NELL1 and NELL2.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 265, no. 1, 11 November 1999 (1999-11-11), pages 79 - 86, XP001051695, ISSN: 0006-291X *
LEVY, EFRAT ET AL: "Stroke in Icelandic patients with hereditary amyloid angiopathy is relate to a mutation in the cystatin C gene, an inhibitor of cysteine proteases", J. EXP. MED. (1989), 169(5), 1771-8, XP001011800 *
LITTLE S P ET AL: "ZYME, A NOVEL AND POTENTIALLY AMYLOIDOGENIC ENZYME CDNA ISOLATED FROM ALZHEIMER'S DISEASE BRAIN", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 40, 1997, pages 25135 - 25142, XP002926885, ISSN: 0021-9258 *
MATTILA K M ET AL: "Altered blood-brain-barrier function in Alzheimer's disease?", ACTA NEUROLOGICA SCANDINAVICA, vol. 89, no. 3, 1994, pages 192 - 198, XP001011873, ISSN: 0001-6314 *
MUN-BRYCE, S. ET AL.: "Matrix Metalloproteinases in Cerebrovascular Disease", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol. 18, 1998, pages 1163 - 1172, XP001051471 *
OYASU MIHO ET AL: "Immunocytochemical localization of a neuron-specific thrombospondin-1-like protein, NELL2: Light and electron microscopic studies in the rat brain.", MOLECULAR BRAIN RESEARCH, vol. 76, no. 1, 10 March 2000 (2000-03-10), pages 151 - 160, XP002949478, ISSN: 0169-328X *
REID ROBERT A ET AL: "Identification and characterization of the human cell adhesion molecule contactin.", MOLECULAR BRAIN RESEARCH, vol. 21, no. 1-2, 1994, pages 1 - 8, XP001052602, ISSN: 0169-328X *
ROMANIC A M ET AL: "MATRIX METALLOPROTEINASE EXPRESSION INCREASES AFTER CEREBRAL FOCAL ISCHEMIA IN RATS INHIBITION OF MATRIX METALLOPROTEINASE-9 REDUCES INFARCT SIZE", STROKE, AMERICAN HEART ASSOCIATION, DALLAS TX, US, vol. 29, no. 5, 1998, pages 1020 - 1030, XP001051490, ISSN: 0039-2499 *
SAKURAI T ET AL: "INDUCTION OF NEURITE OUTGROWTH THROUGH CONTACTIN AND NR-CAM BY EXTRACELLULAR REGIONS OF GLIAL RECEPTOR TYROSINE PHOSPHATASE BETA", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 136, no. 4, 24 February 1997 (1997-02-24), pages 907 - 918, XP001051425, ISSN: 0021-9525 *
WANG X ET AL: "SUBTRACTIVE CLONING IDENTIFIES TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE-1 (TIMP-1) INCREASED GENE EXPRESSION FOLLOWING FOCAL STROKE", STROKE, AMERICAN HEART ASSOCIATION, DALLAS TX, US, vol. 29, no. 2, February 1998 (1998-02-01), pages 516 - 520, XP001051492, ISSN: 0039-2499 *
WATANABE T K ET AL: "CLONING AND CHARACTERIZATION OF TWO NOVEL HUMAN CDNAS (NELL1 AND NELL2) ENCODING PROTEINS WITH SIX EGF-LIKE REPEATS", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 38, no. 3, 15 December 1996 (1996-12-15), pages 273 - 276, XP002064052, ISSN: 0888-7543 *
YAMADA T ET AL: "Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells.", ACTA NEUROPATHOLOGICA, vol. 89, no. 3, 1995, pages 199 - 203, XP001052600, ISSN: 0001-6322 *
YAMASHIRO K ET AL: "Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain", BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, XP002075096, ISSN: 0167-4781 *
YOUSEF G M ET AL: "MOLECULAR CHARACTERIZATION OF ZYME/PROTEASE M/NEUROSIN (PRSS9), A HORMONALLY REGULATED KALLIKREIN-LIKE SERINE PROTEASE", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 62, no. 2, 1999, pages 251 - 259, XP001051426, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
AU2001240820A1 (en) 2001-09-24
WO2001069261A2 (fr) 2001-09-20
EP1264183A2 (fr) 2002-12-11

Similar Documents

Publication Publication Date Title
WO2002054081A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse renale
WO2002059604A8 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques
WO2001075454A3 (fr) Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment
WO2003028543A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees comprenant le diagnostic et le traitement de la maladie d'alzheimer
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2001013117A3 (fr) Proteines et genes destines au diagnostic et au traitement du cancer du sein et leur utilisation
EP2147928A3 (fr) Thérapie d'immunisation à base de peptides pour le traitement de l'athérosclérose et développement d'un dosage à base de peptides pour la détermination des réponses immunes contre une lipoprotéine oxydée à basse densité
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation
WO1996003502A3 (fr) Proteines derivees de muc1 destinees au diagnostic, a l'imagerie et a la therapie du cancer humain
WO1999047925A3 (fr) Procedes et compositions pour le diagnostic de la polyarthrite rhumatoide
WO2002046767A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
WO2001062784A3 (fr) Proteines
WO2001062785A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
WO2002090974A3 (fr) Procede pour depister une maladie dementielle chronique evolutive, et peptides et reactifs de depistage associes
WO2001069261A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
WO2001063294A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de maladies affectives bipolaires (bad) et de depressions unipolaires
EP1283272A3 (fr) Méthodes et moyens d'évaluation d'une thérapie à base des inhibiteurs de l'enveloppe du VIH
DE60101305D1 (de) Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
WO2004098521A3 (fr) Traitement et diagnostics du cancer
WO2002054080A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire
WO2008037720A3 (fr) Moyens et procédés permettant de diagnostiquer et/ou de traiter un sujet courant le risque de développer une insuffisance cardiaque
WO2002046768A3 (fr) Protéines, gènes, et leur utilisation pour le diagnostic et le traitement de l'asthme chronique
WO2001013118A3 (fr) Procedes et compositions permettant le diagnostic de l'hepatome
WO2002002623A3 (fr) Compositions et methodes de diagnostic et de traitement du cancer des poumons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001911898

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001911898

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001911898

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP